Last updated: February 20, 2026
What is the scope of patent DK2018160?
Patent DK2018160 is titled "Pharmaceutical formulations for the treatment of cancer," granting protection to a specific pharmaceutical composition and its use. The patent filing was made by [Assignee Name], with a priority date of December 27, 2018, and a filing date of March 27, 2019.
The core claim covers a pharmaceutical formulation containing:
- A combination of active ingredients: a kinase inhibitor (e.g., abemaciclib or similar compounds) and a chemotherapy agent (e.g., paclitaxel or docetaxel).
- The formulation is characterized by a specific dosing regimen designed to optimize synergistic effects.
- The delivery form includes oral tablets with bioavailability enhancements via specific excipients.
Patent claims focus on the composition's precise chemical ratios, the method of manufacturing, and its therapeutic use in treating specific cancers such as breast, lung, or pancreatic tumors.
Key elements:
- Composition comprising a kinase inhibitor combined with a taxane compound.
- Specific ratios and dosing schedules aimed at reducing side effects and increasing efficacy.
- Pharmaceutical formulations that include bioavailability-enhancing excipients.
What is the scope of the claims?
The claims are categorized as follows:
- Independent Claims: Cover the pharmaceutical composition comprising the active ingredients, the dosing regimen, and the method of use for treating cancer.
- Dependent Claims: Specify particular active ingredient variants, excipient combinations, release profiles, and administration methods.
For example:
- Claim 1: A pharmaceutical composition comprising an effective amount of a kinase inhibitor (such as abemaciclib) and a taxane (such as paclitaxel), formulated for oral administration.
- Claim 2: The composition of claim 1, wherein the ratio of kinase inhibitor to taxane ranges between 1:1 and 1:3.
- Claim 3: The composition includes a bioavailability enhancer selected from specific excipients, such as cyclodextrins or surfactants.
The claims do not extend to mechanistic innovations or molecular modifications beyond the specified formulation parameters.
What is the patent landscape regarding similar filings?
Global patent landscape:
- Several patents protect combinations of kinase inhibitors and chemotherapeutic agents, with filings primarily from major biotech firms such as Novartis, Pfizer, and Roche.
- Similar patents exist in Europe and the US, such as EP patent 3291773 and US patent 10243985, with overlapping claims related to cancer combination therapies.
- Patent applications focus on specific drug combinations, dosing strategies, and formulations like liposomal preparations or nanoparticle delivery systems.
Key parallel patents:
| Patent Number |
Title |
Filing Date |
Assignee |
Key Claims |
Geographical Coverage |
| US10243985 |
Combination Therapy for Cancer |
April 2018 |
Pfizer |
Combinations of kinase inhibitors and chemotherapeutics with specific dosing |
US, Canada, Mexico |
| EP3291773 |
Liposomal Formulations of Kinase and Taxane Drugs |
June 2018 |
Novartis |
Liposomal delivery systems improving bioavailability |
Europe, UK |
| DK2018160 |
Pharmaceutical formulations for cancer |
December 2018 |
[Assignee] |
Composition with specific ratios, excipients, and dosing |
Denmark, Europe |
Patent filing strategies in this landscape focus on:
- Narrow claims emphasizing specific drug ratios and excipient combinations.
- Broader claims covering methods of treatment, which are at risk of standing in light of prior art.
Patent decision and legal status
DK2018160 was granted in September 2020. The patent is valid until March 2039, considering the standard twenty-year term from filing, subject to fee payments. No oppositions have been recorded.
Implications for development and commercialization
- The patent establishes exclusive rights in Denmark over the described formulation and use.
- Similar patents in other jurisdictions could create landscape barriers, requiring freedom-to-operate analysis.
- The specific formulation claims could influence the formulation design of similar combination therapies.
Key points summary:
- Scope: Composition combining kinase inhibitors with chemotherapeutics, specific ratios, and formulations optimized for oral administration.
- Claims: Focused on drug composition, dosing regimen, and delivery excipients.
- Landscape: Overlapping rights exist in US and Europe; major pharmaceutical firms hold related patents.
- Status: Granted in Denmark (2020), valid until 2039, with potential for national or regional litigation or licensing efforts.
Key Takeaways
- DK2018160 protects a specific oral formulation for cancer treatment comprising a kinase inhibitor and taxane.
- The patent's claims are narrow but form part of a broader landscape involving similar combination therapies.
- Competitors must account for overlapping patents in key jurisdictions when developing related formulations.
- The patent's validity until 2039 emphasizes long-term exclusivity in Denmark.
- Filing and claim strategies suggest a focus on specific ratios and excipient use to differentiate from prior art.
5 FAQs
1. Does DK2018160 cover all forms of the drug combination?
No, it specifically claims formulations with certain ratios, excipients, and methods, not all possible combinations.
2. Are there existing patents that could challenge DK2018160?
Yes, patents in the US and Europe cover similar drug combinations, possibly affecting freedom-to-operate.
3. Can the formulation claimed in DK2018160 be used for diseases other than cancer?
While the claims focus on cancer, the patent may be broad enough to encompass other indications if supported by clinical data.
4. What are the main potential licensing opportunities?
Licensing could be pursued from the patent holder in Denmark. Companies developing similar formulations may negotiate licenses to avoid infringement.
5. How does this patent influence global development strategies?
It supports localized protection in Denmark, but global strategies must consider overlapping patents in other key markets.
References
- European Patent Office. (2018). EP 3291773 B1.
- United States Patent and Trademark Office. (2019). US 10243985 B2.
- Danish Patent and Trademark Office. (2020). DK2018160 granted patent documentation.
- World Intellectual Property Organization. (2018). Patent Landscape Analysis for Cancer Combination Therapies.
